Welcome to our dedicated page for Nurix Therapeutics SEC filings (Ticker: NRIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nurix Therapeutics, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines. Its 8-K reports furnish quarterly and annual financial results, corporate presentations, clinical-program updates for bexobrutideg and pipeline programs, and other material events tied to research, development and financing activity.
The company’s SEC disclosures also cover its common stock listed on the Nasdaq Global Market, shelf registration and at-the-market equity distribution arrangements, underwritten equity offerings, and use-of-proceeds language tied to clinical development and research programs. Proxy and governance filings document board composition, director appointments, compensation programs, committee assignments and annual stockholder meeting matters.
FMR LLC reports 5,541,271.11 shares (5.4%) of Nurix Therapeutics common stock as beneficially owned as of 03/31/2026. The filing of a Schedule 13G states that FMR LLC holds 5,541,271.11 shares with sole dispositive power and sole voting power reported on the cover. The filing also lists Abigail P. Johnson as having shared attribution to the same 5,541,271.11 shares. The filing notes that one or more other persons may have rights to dividends or sale proceeds but no single outside person holds over 5% individually. Exhibit references and a power of attorney are attached.
Nurix Therapeutics, Inc.’s Chief Financial Officer Hans van Houte reported open-market sales of company stock. On May 5, 2026, he sold a total of 14,055 shares of common stock in two transactions pursuant to a previously adopted Rule 10b5-1 trading plan.
The reported sales covered 13,473 shares at $16.5756 per share and 582 shares at $17.1751 per share, each representing a weighted average sale price across multiple trades within stated price ranges.
Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring reported an open-market sale of 8,148 shares of common stock at a weighted average price of $16.9624 per share. The transaction was executed pursuant to a previously adopted Rule 10b5-1 trading plan. Following this sale, she holds 18,305 shares directly.
Issuer affiliate filed a Form 144 listing 8,148 shares of Common Stock for sale. The filing also lists multiple 10b5-1 sales by Christine Ring in early 2026, including transactions on 05/01/2026 (5,394 shares, $90,406.68) and 04/30/2026 (3,214 shares, $53,497.99). The securities reported as issuable were Restricted Stock Units dated 05/02/2022.
Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring reported an open-market sale of 5,394 shares of common stock on May 1, 2026 at a weighted average price of $16.7606 per share. The sale was executed under a previously adopted Rule 10b5-1 trading plan, with individual sale prices ranging from $16.26 to $16.97. Following this transaction, she directly holds 26,453 shares of Nurix common stock.
The filing is a Form 144 notice reporting proposed sales of Common Stock tied to Restricted Stock Units. The document lists 5,394 RSUs with an effective/record date of 04/30/2026 and multiple planned or effected 10b5-1 sales by Christine Ring on dates in 02/09/2026, 03/02/2026, 04/02/2026, and 04/30/2026.
Nurix Therapeutics Chief Financial Officer Hans van Houte reported routine equity compensation activity tied to restricted stock units (RSUs). On April 30, 2026, RSUs covering 8,608 shares of common stock vested and were converted into common shares.
To satisfy associated tax withholding obligations, 2,388 common shares were sold in an open-market transaction at a weighted average price of $16.6453 per share. The company’s equity plan required this "sell to cover" transaction, and the filing states it did not represent a discretionary trade by the executive.
Following these transactions, Hans van Houte directly holds 51,647 shares of Nurix common stock. The RSU awards vest in quarterly installments over three years, with separate grants beginning to vest on July 30, 2023, July 30, 2024, and July 30, 2025, contingent on continued service. Each RSU represents a right to receive one share of common stock upon vesting.
Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring had restricted stock units vest and related share movements on April 30, 2026. She sold 3,214 shares of common stock at a weighted average of $16.6453 per share solely to cover tax withholding on the RSU vesting, under the company’s mandatory “sell to cover” policy, so the sale was not a discretionary trade. In connection with the vesting, she acquired a total of 8,608 shares of common stock through RSU conversions.
Nurix Therapeutics, Inc. Chief Scientific Officer Gwenn Hansen reported compensation-related stock activity involving vested restricted stock units and a small mandated share sale. On April 30, 2026, she exercised RSUs into a total of 8,608 shares of common stock.
On the same date, she sold 3,214 shares of common stock at a weighted average price of $16.6453 per share solely to cover tax withholding obligations under Nurix’s equity incentive plans. These “sell to cover” transactions were not discretionary trades. After these transactions, she held 120,399 common shares directly.